| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N Naha, S P Li, B C Yang, T J Park, M O Ki. Time-dependent exposure of nicotine and smoke modulate ultrasubcellular organelle localization of dopamine D1 and D2 receptors in the rat caudate-putamen. Synapse (New York, N.Y.). vol 63. issue 10. 2009-10-26. PMID:19562699. |
the correlation of the subcellular localization of dopamine d(1) and d(2) receptors (da d(1) r, da d(2) r) with nicotine addiction has not been studied. |
2009-10-26 |
2023-08-12 |
rat |
| Jianrong Tang, John A Dan. Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron. vol 63. issue 5. 2009-10-13. PMID:19755109. |
dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. |
2009-10-13 |
2023-08-12 |
mouse |
| Krista Spiller, Zheng-Xiong Xi, Xia Li, Charles R Ashby, Patrick M Callahan, Ashok Tehim, Eliot L Gardne. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology. vol 57. issue 1. 2009-10-01. PMID:19393252. |
varenicline, a partial alpha4beta2 and full alpha7 nicotinic receptor agonist, has been shown to inhibit nicotine self-administration and nicotine-induced increases in extracellular dopamine in the nucleus accumbens. |
2009-10-01 |
2023-08-12 |
rat |
| Linda P Dwoskin, Andrew M Smith, Thomas E Wooters, Zhenfa Zhang, Peter A Crooks, Michael T Bard. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical pharmacology. vol 78. issue 7. 2009-09-21. PMID:19523455. |
the major alkaloid in tobacco, nicotine, activates nicotinic receptors (nachrs) which increase brain extracellular dopamine producing nicotine reward leading to addiction. |
2009-09-21 |
2023-08-12 |
Not clear |
| Linda P Dwoskin, Andrew M Smith, Thomas E Wooters, Zhenfa Zhang, Peter A Crooks, Michael T Bard. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical pharmacology. vol 78. issue 7. 2009-09-21. PMID:19523455. |
subtype-selective nachr antagonists that block reward-relevant mesocorticolimbic and nigrostriatal dopamine release induced by nicotine may offer advantages over current therapies. |
2009-09-21 |
2023-08-12 |
Not clear |
| Linda P Dwoskin, Andrew M Smith, Thomas E Wooters, Zhenfa Zhang, Peter A Crooks, Michael T Bard. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical pharmacology. vol 78. issue 7. 2009-09-21. PMID:19523455. |
an innovative approach is to provide pharmacotherapies which are antagonists at nachr subtypes mediating nicotine evoked dopamine release. |
2009-09-21 |
2023-08-12 |
Not clear |
| Anitha P Govind, Paul Vezina, William N Gree. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochemical pharmacology. vol 78. issue 7. 2009-09-21. PMID:19540212. |
mounting evidence suggests that the addictive effects of nicotine, like other drugs of abuse, occur through interactions with its receptors in the mesolimbic dopamine system, particularly ventral tegmental area (vta) neurons, where nicotinic receptors act to modulate the release of dopamine. |
2009-09-21 |
2023-08-12 |
Not clear |
| Andrew M Smith, Gurpreet K Dhawan, Zhenfa Zhang, Kiran B Siripurapu, Peter A Crooks, Linda P Dwoski. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochemical pharmacology. vol 78. issue 7. 2009-09-21. PMID:19631612. |
previous studies determined that bpiddb potently (ic(50)=2 nm) inhibits nicotine-evoked striatal [(3)h]dopamine (da) release in vitro, nicotine-evoked da release in nucleus accumbens in vivo, and nicotine self-administration in rats. |
2009-09-21 |
2023-08-12 |
rat |
| Huibing Tan, Stephanie F Bishop, Nicole M Lauzon, Ninglei Sun, Steven R Laviolett. Chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. Neuropharmacology. vol 56. issue 4. 2009-09-17. PMID:19133278. |
chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. |
2009-09-17 |
2023-08-12 |
human |
| Huibing Tan, Stephanie F Bishop, Nicole M Lauzon, Ninglei Sun, Steven R Laviolett. Chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. Neuropharmacology. vol 56. issue 4. 2009-09-17. PMID:19133278. |
the mammalian ventral tegmental area (vta) and associated mesolimbic dopamine (da) system are critical neural substrates for processing nicotine's motivational effects. |
2009-09-17 |
2023-08-12 |
human |
| Edward F Domino, Hideo Tsukada, Norihiro Harad. Positron emission tomographic measure of brain dopamine dependence to nicotine as a model of drugs of abuse. Psychopharmacology. vol 204. issue 1. 2009-09-02. PMID:19137279. |
positron emission tomographic measure of brain dopamine dependence to nicotine as a model of drugs of abuse. |
2009-09-02 |
2023-08-12 |
Not clear |
| Edward F Domino, Hideo Tsukada, Norihiro Harad. Positron emission tomographic measure of brain dopamine dependence to nicotine as a model of drugs of abuse. Psychopharmacology. vol 204. issue 1. 2009-09-02. PMID:19137279. |
nicotine abstinence produces some depressive-like effects which are treated by the dopamine (da) and norepinephrine reuptake inhibitor bupropion. |
2009-09-02 |
2023-08-12 |
Not clear |
| Darlene H Brunzell, Yann S Mineur, Rachael L Neve, Marina R Picciott. Nucleus accumbens CREB activity is necessary for nicotine conditioned place preference. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 8. 2009-09-02. PMID:19212318. |
the ability of nicotine to alter firing of dopamine neurons is the first step leading to nicotine reward, but activation of intracellular signaling pathways downstream of nicotinic acetylcholine receptors is likely to be critical for longer-term consequences of nicotine exposure, including conditioned reward. |
2009-09-02 |
2023-08-12 |
mouse |
| Isabel R Schlaepfer, Nicole R Hoft, Marissa A Ehringe. The genetic components of alcohol and nicotine co-addiction: from genes to behavior. Current drug abuse reviews. vol 1. issue 2. 2009-08-28. PMID:19492010. |
the nachrs are important components of the dopaminergic reward system because some of the receptors have been shown to activate the release of dopamine, and mice lacking genes for specific nachr gene subunits show altered behavioral responses to nicotine and alcohol. |
2009-08-28 |
2023-08-12 |
mouse |
| Emmanuel Itti, Gabriel Villafane, Zoulikha Malek, Pierre Brugières, Daniela Capacchione, Laurent Itti, Patrick Maison, Pierre Cesaro, Michel Meigna. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nuclear medicine communications. vol 30. issue 7. 2009-08-24. PMID:19451839. |
dopamine transporter imaging under high-dose transdermal nicotine therapy in parkinson's disease: an observational study. |
2009-08-24 |
2023-08-12 |
Not clear |
| Emmanuel Itti, Gabriel Villafane, Zoulikha Malek, Pierre Brugières, Daniela Capacchione, Laurent Itti, Patrick Maison, Pierre Cesaro, Michel Meigna. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nuclear medicine communications. vol 30. issue 7. 2009-08-24. PMID:19451839. |
this observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy. |
2009-08-24 |
2023-08-12 |
Not clear |
| Robert E Sorge, Paul B S Clark. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. The Journal of pharmacology and experimental therapeutics. vol 330. issue 2. 2009-08-19. PMID:19448141. |
rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. |
2009-08-19 |
2023-08-12 |
rat |
| Marcus R Munafò, Elaine C Johnstone, Michael F G Murphy, Paul Aveyar. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. vol 11. issue 4. 2009-08-05. PMID:19273465. |
we previously reported evidence that the t allele of the dopamine type-2 receptor (drd2) rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (nrt) relative to placebo and that this association may only be present in females. |
2009-08-05 |
2023-08-12 |
Not clear |
| Zheng-xiong Xi, Krista Spiller, Eliot L Gardne. Mechanism-based medication development for the treatment of nicotine dependence. Acta pharmacologica Sinica. vol 30. issue 6. 2009-07-31. PMID:19434058. |
nicotine binds to alpha4beta2 and alpha7 nicotinic acetylcholine receptors (nachrs) located on dopaminergic, glutamatergic and gabaergic neurons in the mesolimbic dopamine (da) system, which causes an increase in extracellular da in the nucleus accumbens (nac). |
2009-07-31 |
2023-08-12 |
Not clear |
| Edward F Domino, Hideo Tsukad. Nicotine sensitization of monkey striatal dopamine release. European journal of pharmacology. vol 607. issue 1-3. 2009-07-07. PMID:19232339. |
nicotine sensitization of monkey striatal dopamine release. |
2009-07-07 |
2023-08-12 |
human |